CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+18.11%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$514M
AUM Growth
+$169M
(+49%)
Cap. Flow
+$116M
Cap. Flow
% of AUM
22.65%
Top 10 Holdings %
Top 10 Hldgs %
26.88%
Holding
503
New
57
Increased
239
Reduced
90
Closed
78
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$6.88M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$6.46M |
| 3 |
Gilead Sciences
GILD
|
$6.38M |
| 4 |
Amgen
AMGN
|
$6.24M |
| 5 |
Adobe
ADBE
|
$5.19M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$5.18M |
| 2 |
Analog Devices
ADI
|
$3.75M |
| 3 |
Amazon
AMZN
|
$3.48M |
| 4 |
lululemon athletica
LULU
|
$3.4M |
| 5 |
iQIYI
IQ
|
$1.91M |
Sector Composition
| 1 | Technology | 34.39% |
| 2 | Healthcare | 30.05% |
| 3 | Consumer Discretionary | 17.55% |
| 4 | Communication Services | 6.11% |
| 5 | Consumer Staples | 4.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Biomea Fusion
BMEA
$114M
| $60K | 0.01% |
4,131
+3,210
| +349% | +$46.6K |
|
352
Caribou Biosciences
CRBU
$174M
| $58.6K | 0.01% |
10,226
+7,968
| +353% | +$45.7K |
|
353
Cogent Biosciences
COGT
$1.82B
| $58.6K | 0.01% |
9,961
+7,772
| +355% | +$45.7K |
|
354
Oric Pharmaceuticals
ORIC
$1.06B
| $58K | 0.01% |
+6,305
| New | +$58K |
|
355
Nurix Therapeutics
NRIX
$758M
| $57.9K | 0.01% |
5,611
+4,367
| +351% | +$45.1K |
|
356
Wave Life Sciences
WVE
$1.32B
| $57.9K | 0.01% |
11,456
+8,920
| +352% | +$45K |
|
357
MongoDB
MDB
$26.4B
| $57.6K | 0.01% |
+141
| New | +$57.6K |
|
358
Replimune Group
REPL
$494M
| $57.6K | 0.01% |
6,833
+5,324
| +353% | +$44.9K |
|
359
Janux Therapeutics
JANX
$1.44B
| $57.3K | 0.01% |
+5,343
| New | +$57.3K |
|
360
Lyell Immunopharma
LYEL
$233M
| $56.5K | 0.01% |
1,457
+1,135
| +352% | +$44K |
|
361
MaxCyte
MXCT
$150M
| $56.3K | 0.01% |
11,986
+9,323
| +350% | +$43.8K |
|
362
Warner Bros
WBD
$30B
| $56.1K | 0.01% |
4,932
-4,150
| -46% | -$47.2K |
|
363
Diamondback Energy
FANG
$40.2B
| $54.7K | 0.01% |
353
-313
| -47% | -$48.5K |
|
364
Take-Two Interactive
TTWO
$44.2B
| $54.6K | 0.01% |
+339
| New | +$54.6K |
|
365
UroGen Pharma
URGN
$873M
| $53.6K | 0.01% |
3,575
+2,801
| +362% | +$42K |
|
366
MeiraGTx Holdings
MGTX
$619M
| $51.6K | 0.01% |
7,354
+5,832
| +383% | +$40.9K |
|
|
THRD
367
DELISTED
Third Harmonic Bio
THRD
| $51.2K | 0.01% |
+4,665
| New | +$51.2K |
|
|
SPLK
368
DELISTED
Splunk Inc
SPLK
| $51K | 0.01% |
+335
| New | +$51K |
|
|
CNTA
369
Centessa Pharmaceuticals
CNTA
$2.11B
| $50.9K | 0.01% |
6,394
+5,037
| +371% | +$40.1K |
|
370
Cullinan Oncology
CGEM
$413M
| $50.5K | 0.01% |
4,954
+3,859
| +352% | +$39.3K |
|
371
KalVista Pharmaceuticals
KALV
$796M
| $48.8K | 0.01% |
+3,981
| New | +$48.8K |
|
|
CAN
372
Canaan Creative
CAN
$346M
| $48.5K | 0.01% |
+21,000
| New | +$48.5K |
|
373
Arbutus Biopharma
ABUS
$805M
| $48.5K | 0.01% |
19,400
+15,104
| +352% | +$37.8K |
|
374
AC Immune
ACIU
$229M
| $48.4K | 0.01% |
+9,674
| New | +$48.4K |
|
375
Fulcrum Therapeutics
FULC
$414M
| $48.3K | 0.01% |
7,150
+5,556
| +349% | +$37.5K |
|